Inovio Pharmaceuticals (INO) receives an additional $6.9 million
Inovio Pharmaceuticals (INO) currently trades at $7.70 and has grown by 7.90% today. INO went up $0.56 from the previous closing price of $7.14. The high forecast for Inovio Pharmaceuticals is $13.00 and the low is $7.00. The company’s market cap is $1.12 billion with a 52 week high of $19.36 and a 52 week low of $1.92. INO has changed in price by 3.95 per share in the last 12 months. The company announced that it had received an additional $6.9 million to fund a Phase 1/2 clinical trial of its COVID-19 vaccine candidate in South Korea. The funding came from the Coalition for Epidemic Preparedness Innovations (CEPI), an Oslo-based organization that has provided funding to vaccine makers during the pandemic.
Inovio Pharmaceuticals has a weak EPS of -1.21. This means the company lost $-1.21 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information written in this article.
About Inovio Pharmaceuticals:
Inovio’s technology platform is capable of activating antigen-specific immune responses. With demonstrated efficacy in a Phase 2b trial, robust and targeted immune responses, a favorable safety profile, and a robust pipeline of product candidates across multiple disease states, the evidence to date is clear—Inovio is realizing the true promise of immunotherapy.